Indolent Lymphoma: Well Tolerated, Fixed Duration Treatment Involving Bendamustine, Rituximab and Acalabrutinib for Front-Line Waldenstrom's Macroglobulinaemia That Induce Deep Clinical Responses Journal Articles uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Suleman, Adam
  • Roos, Kim
  • Mangoff, Kathryn
  • Jiang, Yidi
  • Klein, Gail
  • Mcclure, Rebecca
  • Forward, Nicholas Allen
  • Shafey, Mona
  • Nikonova, Anna
  • Sebag, Michael
  • Macdonald, David
  • Villa, Diego
  • Sandhu, Irwindeep
  • Aljama, Mohammed
  • Larouche, Jean-Francois
  • Simmons, Heidi
  • Gallucci, Monica
  • Tomlinson, George A
  • Berinstein, Neil

publication date

  • November 5, 2024

published in